Similarly, all Group 1 markers showed significantly higher methylation levels in BRAF‐mutation(+) CRC than KRAS‐mutation(+) and NRAS‐mutation(+) CRC (P < 0.05) (Fig. 3). Here, KRAS is linked to colorectal carcinoma.